Cytokinetics Inc. (CYTK) Dividend History

Company News

• Cytokinetics Presents Additional Data Related to Aficamten at the European Society of Cardiology Heart Failure 2025 Congress

  Cytokinetics presented additional data from the SEQUOIA-HCM trial on the efficacy of aficamten in patients with obstructive hypertrophic cardiomyopathy, as well as real-world data on disparities in outcomes for females and older patients with non-obstructive HCM.

  GlobeNewswire Inc.
• Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

  Cytokinetics, a specialty cardiovascular biopharmaceutical company, announced four upcoming presentations at the European Society of Cardiology Heart Failure 2025 Congress, including three Late Breaking Science presentations and one ePoster presentation.

  GlobeNewswire Inc.
• Cytokinetics to Hold Annual Meeting of Stockholders

  Cytokinetics announced that the FDA has extended the PDUFA date for its drug aficamten in obstructive hypertrophic cardiomyopathy to December 26, 2025. The company also provided updates on other clinical trials.

  GlobeNewswire Inc.
• FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

  The FDA has extended the PDUFA action date for Cytokinetics' new drug application for aficamten, an experimental heart drug, by three months to allow for a full review of the company's proposed Risk Evaluation and Mitigation Strategy (REMS).

  Benzinga

  Featured Companies: BMY
• Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  Cytokinetics, a biopharmaceutical company, announced granting stock options and restricted stock units to 13 new employees as a material inducement to their employment. The awards are subject to the company's equity incentive plan and vesting schedules.

  GlobeNewswire Inc.